Lynparza stalls pancreatic cancer in patients with BRCA mutations: study
AstraZeneca and Merck & Co's Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go longer without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday.
from Reuters: Health News https://reut.rs/2Z9NSQb
http://bit.ly/2zwRqiM